Format

Send to

Choose Destination
J Hepatol. 2018 Apr;68(4):864-866. doi: 10.1016/j.jhep.2017.11.044. Epub 2018 Jan 12.

Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".

Author information

1
MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.
2
Gastrointestinal and Liver Disorders Theme, NIHR Nottingham Biomedical Research Centre at the Nottingham University Hospitals NHS Trust and the University of Nottingham, UK.
3
Blizard Institute, Queen Mary University of London, London, UK.
4
Institute of Liver Studies, King's College Hospital Foundation Trust, London UK.
5
Institute of Liver and Digestive Health, University College of London, London, United Kingdom.
6
Royal Liverpool University NHS Trust, Liverpool, UK.
7
Liver Unit, St James's University Hospital, Leeds, UK.
8
Infectious Diseases Unit, University Hospitals Leicester NHS Trust, Leicester, UK.
9
Infectious Diseases, North Manchester General Hospital, Manchester, UK.
10
MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. Electronic address: john.mclauchlan@glasgow.ac.uk.
PMID:
29339112
DOI:
10.1016/j.jhep.2017.11.044
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center